High adherence with a low initial ribavirin dose in combination with pegylated-IFN alpha-2a for treatment of recurrent hepatitis C after liver transplantation
Authors:
- Henrik GjertsenHGHenrik Gjertsen
- Ola WeilandOWOla Weiland
- 1 January 2008
- journal article
- clinical trial
- Published by Taylor & Francis in Scandinavian Journal of Infectious Diseases
- Vol. 40 (3) , 259-265
Abstract
Patients with recurrent hepatitis C after liver transplantation often cannot tolerate full dose of pegylated interferon (peg-IFN) and ribavirin (RBV) and are often withdrawn prematurely from treatment. We chose a low initial RBV dose, later increased due to tolerance to a mean dose of 600 mg daily (range 200-1000 mg daily) in combination with a peg-IFN alpha-2a 180 mcg weekly in an effort to improve tolerance and minimize withdrawals. 16 patients with hepatitis C recurrence and 1 with de novo HCV infection with a mean age of 54 y (range 43-66 y), 71% males, were treated. All patients completed the intended treatment schedule 24 weeks for genotype 2 and 3 and 48 weeks for genotype 1 and 4. Early viral response was achieved in 12 (71%), non-response in 1 patient with genotype 4, and sustained viral response in 4/5 (80%) patients with genotype 2 or 3 and 3/11 (27%) with genotype 1, p<0.05. To conclude, we found that utilizing a low initial daily RBV dose, later increased due to tolerance in combination with peg-IFN alpha-2a 180 microg weekly, was successful. Hence, all patients completed a full treatment course, which also offered a reasonable efficacy.Keywords
This publication has 24 references indexed in Scilit:
- Impact of Ribavirin Dose Reductions in Hepatitis C Virus Genotype 1 Patients Completing Peginterferon Alfa-2a/Ribavirin TreatmentClinical Gastroenterology and Hepatology, 2007
- Liver Transplantation for HCV Cirrhosis at Karolinska University Hospital Huddinge, StockholmTransplantation Proceedings, 2006
- Treating hepatitis C infection in liver transplant recipientsLiver Transplantation, 2006
- Treatment of HCV recurrence: Do the pretransplantation rules apply?Liver Transplantation, 2006
- Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis CLiver Transplantation, 2006
- Antiviral treatment of recurrent hepatitis C after liver transplantationHepatology, 2005
- Peginterferon-α2a and Ribavirin Combination Therapy in Chronic Hepatitis CAnnals of Internal Medicine, 2004
- Interferon-α 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: A randomized studyGastroenterology, 2003
- Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus InfectionNew England Journal of Medicine, 2002
- Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantationHepatology, 2000